Vimarsana
Biggest News Aggregation in the World

Pavan Cheruvu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pavan Cheruvu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pavan Cheruvu Today - Breaking & Trending Today

Bitterroot Bio and Biotheus Announce Research Collaboration - Vimarsana News

Bitterroot Bio and Biotheus Announce Research Collaboration

Collaboration aims to discover novel bispecific proteins targeting immune modulators and inflammatory pathways implicated in cardiovascular disease...

Signs of Trouble Emerge as Sio Gene Halts UMass Gangliosidosis Deal - Vimarsana News

Signs of Trouble Emerge as Sio Gene Halts UMass Gangliosidosis Deal

Sio Gene has terminated its licensing deal with the UMass to develop and commercialize two gene therapy product candidates to focus on more potentially profitable projects. 

Chutes & Ladders—Pfizer poaches Roche's early R&D leader Pao to replace development chief - Vimarsana News

Chutes & Ladders—Pfizer poaches Roche's early R&D leader Pao to replace development chief

Pfizer picks from Roche's executive team, snagging pharma early R&D leader William Pao as the Big Pharma's next chief development officer. Leo Pharma poaches from ... a Danish meme stock for its new CEO, who will lead a reorganization of the dermatology biopharma. And Sio Gene Therapies CEO Cheruvu is out the door as Parkinson's program also hits the exit.

Oxford Biomedica Says Sio Gene Intends To End AXO-Lenti-PD License Deal - Vimarsana News

Oxford Biomedica Says Sio Gene Intends To End AXO-Lenti-PD License Deal

LONDON (dpa-AFX) - British gene and cell therapy company Oxford Biomedica Plc (OXB), said that Sio Gene Therapies has informed that it intends to return the global rights for AXO-Lenti-PD, a gene

Chutes & Ladders—Athira CEO resigns after investigation confirms she altered research - Vimarsana News

Chutes & Ladders—Athira CEO resigns after investigation confirms she altered research

Athira Pharma's CEO resigns after investigation confirms she altered research during graduate school. vTv Therapeutics named healthcare investor Deepa Prasad its new CEO and president. Opus Genetics snagged a new chief scientific officer and chief operating officer.